Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Exhalation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Exhalation. Displaying page 1 of 1.
    EudraCT Number: 2007-000267-17 Sponsor Protocol Number: VPI-103-01 Start Date*: 2007-02-21
    Sponsor Name:Verus Pharmaceuticals Inc
    Full Title: A SINGLE CENTRE, GAMMA SCINTIGRAPHY STUDY IN ASTHMATIC PATIENTS TO COMPARE PULMONARY DEPOSITION AND PHARMACOKINETICS OF ALBUTEROL INHALATION SOLUTION (AIS) DELIVERED VIA eFLOW NEBULISER AND SALBUTA...
    Medical condition: The medical condition which is under investigation is Asthma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000973-38 Sponsor Protocol Number: 14-026 Start Date*: 2014-05-14
    Sponsor Name:RWTH Aachen vertreten durch das CTC-A
    Full Title: Xenon-inhalation: elimination of xenon and its effect on erythropoetin-levels in blood of healthy volunteers
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007094-23 Sponsor Protocol Number: Nitrous oxide protocol V5 Start Date*: 2008-10-09
    Sponsor Name:University of Nottingham
    Full Title: Nitrous oxide and cerebral vasodilatation: a dose-response study in healthy volunteers
    Medical condition: The study will be conducted in healthy volunteers. I will evaluate the effects of inhaled concentrations of nitrous oxide, ranging from 0% to 50%, on cerebral blood flow and cerebral vascular tone ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003774-27 Sponsor Protocol Number: BC-180-12 Start Date*: 2014-01-20
    Sponsor Name:AlgiPharma AS
    Full Title: An open label, randomised, two-way crossover scintigraphic study to investigate lung deposition of radiolabelled OligoG delivered as a dry powder and as a nebulised solution in cystic fibrosis pati...
    Medical condition: Cystic fibrosis (CF) is an autosomal, recessive inheritable disease caused by a homozygote defect at the long arm of Chromosome 7. This mutation causes absence or defect of the cystic fibrosis tran...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001768-39 Sponsor Protocol Number: SURFABRON Start Date*: 2018-03-07
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Randomized multicentre-controlled, placebo-controlled (1: 1) study to evaluate the efficacy and safety of Curosurf in patients under 12 months of age with moderate or severe acute respiratory distr...
    Medical condition: Acute severe hypoxic bronchiolitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10000686 Acute bronchiolitis LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002899-25 Sponsor Protocol Number: CQVM149B2302 Start Date*: 2015-12-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, 52-week, double-blind, parallel-group, active-controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) DE (Completed) SK (Completed) PT (Completed) AT (Completed) HU (Completed) NL (Completed) FI (Completed) BE (Completed) ES (Completed) DK (Completed) LV (Completed) GR (Completed) FR (Completed) BG (Completed) IE (Completed) HR (Completed) SI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000368-12 Sponsor Protocol Number: OPN-FLU-CS-3205 Start Date*: 2019-10-01
    Sponsor Name:OptiNose US, Inc.
    Full Title: A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (...
    Medical condition: Chronic sinusitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10009137 Chronic sinusitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-000648-86 Sponsor Protocol Number: OPN-FLU-CS-3206 Start Date*: 2019-10-01
    Sponsor Name:OptiNose US, Inc.
    Full Title: A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (B...
    Medical condition: Chronic rhinosinusitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10009137 Chronic sinusitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) PL (Completed) ES (Ongoing) BG (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-005534-20 Sponsor Protocol Number: 05102006 Start Date*: 2008-01-24
    Sponsor Name:Imperial College London
    Full Title: Effect of Erdosteine on inflammatory and oxidative biomarkers in sputum and exhaled breath in patients with COPD
    Medical condition: Chronic obstructive pulmonary disease (COPD) of different severity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003681-87 Sponsor Protocol Number: BMN-044-201 Start Date*: 2016-01-12
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A multi center, multi national, open label, extension study to evaluate the long-term efficacy and safety of BMN 044 (PRO044) in subjects with Duchenne muscular dystrophy
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000495-28 Sponsor Protocol Number: 132 Start Date*: 2017-05-18
    Sponsor Name:Respiratory Research Unit, Bispebjerg University Hospital
    Full Title: SIGNATURE - the 6-gene signature as a predictor of response to treatment in severe asthma and ACOS
    Medical condition: Severe asthma and astma-COPD overlap syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077006 Asthma-COPD overlap syndrome LLT
    20.0 100000004855 10003561 Asthma, unspecified LLT
    20.0 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001824-39 Sponsor Protocol Number: CMID001A2201 Start Date*: 2013-05-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, double-dummy, placebo-controlled, 3-period crossover study to evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of orally inhaled indacaterol admi...
    Medical condition: Persistent Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001955-54 Sponsor Protocol Number: BMN-051-302 Start Date*: 2015-12-08
    Sponsor Name:BioMarin Nederland BV
    Full Title: An open-label extension study of the long-term safety, tolerability and efficacy of drisapersen in subjects with Duchenne Muscular Dystrophy.
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: NL (Prematurely Ended) DE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-005615-92 Sponsor Protocol Number: CQBM076X2203 Start Date*: 2013-11-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A two part, double blind, placebo controlled, study to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of multiple doses of QBM076 in patients with COPD
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) NL (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010714-30 Sponsor Protocol Number: 1275148SCD2001 Start Date*: 2009-10-23
    Sponsor Name:Janssen Biologics B.V.
    Full Title: A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar...
    Medical condition: Chronic sarcoidosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039486 Sarcoidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) DK (Completed) FR (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000472-22 Sponsor Protocol Number: CQVM149B2303 Start Date*: 2017-03-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, 12-week treatment, double blind study to assess the efficacy and safety of QMF149 (150/80 microgram) compared with MF Twisthaler® (200 microgram) in adult and adolescent...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed) IT (Completed) SE (Completed) LT (Completed) SK (Completed) LV (Completed) HU (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 23:03:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA